Maine Naloxone Distribution Initiative

Project-To-Date Totals through September 30, 2026

Prepared by the Margaret Chase Smith Policy Center
University of Maine

In July 2019, the Maine Naloxone Distribution Initiative (MNDI) launched an overdose education, prevention, and naloxone distribution project. Public health and harm reduction partners, known as Tier 1 Distributors, began distributing state-supplied naloxone rescue kits across Maine to clinicians, community partners, and end users. This brief provides information on naloxone distribution and reported overdose reversals by the Tier 1 organizations comprising the MNDI from the initiation of the project through September 2026, with a particular emphasis on the third quarter of 2026. Additionally, subcategories of naloxone distribution from Tier 1 organizations to the Overdose Prevention Through Intensive Outreach Naloxone and Safety (OPTIONS) initiative and syringe services/access programs in 2021 as well as EMS Naloxone Leave Behind Program are provided.

Tier 1 organizations include Bangor Public Health (BPH), Portland Public Health (PPH), MaineGeneral Health (MG), and Maine Access Points (MAP). BPH serves the Aroostook, Downeast, and Penquis public health districts, PPH serves Cumberland and York, and MG serves Central, Midcoast, and Western. MAP distributes naloxone statewide with a particular focus on rural regions. Data from the Office of the Attorney General's (OAG) law enforcement administered naloxone program have also been included to provide an overview of the combined public health, harm reduction, and public safety efforts in Maine.

Currently, it is hard to measure the effectiveness of naloxone distribution because the total number of overdose reversals relies on voluntary reporting. The distribution and reported reversal data tables and figure in this report offer conservative estimates of the lives saved through public health, harm reduction, and safety efforts, which prevented the number of drug deaths from potentially being much higher.




Figure 1: County-level naloxone distribution levels per 1000 residents (with point of initial township distribution indicated by star) by the Maine Naloxone Distribution Initiative from July through September 2026.

Monthly proportions of fatalities during January–September 2026 averaged 4.8%, ranging from a high of 6.9% in September to a low of 3.6% in March. During 2025, monthly proportions of fatalities averaged 5.2%, ranging from a high of 6.4% in December to a low of 3.3% in September (Sorg et al. 2026). Additional resources, data, and visualizations are available at the Maine Drug Data Hub: https://mainedrugdata.org/.

Public Health—Tier 1 Distributors

During the third quarter of 2026 (July–September):

27,578 doses of naloxone have been distributed
491 overdose reversals have been voluntarily reported.

From July 2019 through September 2026 (MNDI project-to-date totals):

915,822 doses of naloxone have been distributed
11,446 overdose reversals have been voluntarily reported.

Public Safety—Law Enforcement Agencies

During the third quarter of 2026 (July–September):

1,100 doses of naloxone have been distributed
22 overdose reversals have been voluntarily reported.

From July 2019 through September 2026:

25,756 doses of naloxone have been distributed
1,966 overdose reversals have been voluntarily reported.

Table 1 Doses of naloxone distributed by Tier 1 distributors and OAG

	2019–2024	2025	Jan–Mar 2026	Apr–Jun 2026	Jul 2026	Aug 2026	Sep 2026	Total
BPH (IN)	140320	41806	1388	22014	0	160	3858	209546
BPH (RI)	4416	4152	4032	10704	0	0	0	23304
BPH (IM)	0	14800	0	6400	0	0	0	21200
PPH (IN)	120345	29786	4870	10286	1718	1396	2676	171077
PPH (IM)	3648	2530	200	144	0	50	0	6572
PPH (RI)	0	4	0	0	0	0	0	4
MG	111242	42678	10918	27768	1286	1902	3034	198828
MAP (IM)	163135	19582	4196	3504	1088	1384	2434	195323
MAP (IN)	50436	4302	3728	3658	840	1376	2112	66452
MAP (RI)	2454	14322	450	4026	728	616	920	23516
OAG	21504	1732	1050	370	524	300	276	25756
Total	617500	175694	30832	88874	6184	7184	15310	941578

Notes: (1) Unit is doses for all values. (2) IM = intramuscular; IN = intranasal; RI = RiVive. All values are IN unless otherwise indicated. (3) MAP distribution initially included state-supplied and nonstate-supplied naloxone. (4) 2019 data is for July through December only. (5) A revision has been made to BPH 2020 and 2021, to PPH 2021, 2022, and Apr 2026, and to MG 2020, 2021, 2022, and December 2025. OBH 2019, 2020, 2021, and 2022. (5) Table 1 includes corrections for MAP reporting that include a decrease in IN doses and an increase in IM doses. 1957 doses of IN naloxone were removed from distribution data from 07/2019 to 07/2023 and 13926 doses of IM naloxone were added to distribution data from 07/2019 to 07/2023. (6) Beginning June of 2024, the MNDI will be purchasing and distributing lower dose (3mg) naloxone (RiVive). (7) BPH naloxone purchase and distribution was delayed Jul–Sep 2025 due to pending contracting delays. (8) The Office of the Attorney General purchase and distribution of naloxone was delayed Nov-Jan 2025 due to pending decision for continuance with the MNDI.

Table 1.1 Doses of naloxone distributed by Tier 1 distributors to OPTIONS liaisons (subcategory of total distribution)

	2021–2024	2025	Jan–Mar 2026	Apr–Jun 2026	Jul 2026	Aug 2026	Sep 2026	Total
BPH	12338	8132	0	7672	0	0	816	28958
PPH	6698	5206	816	2904	72	192	28	15916
MG	14012	4200	816	3480	144	96	312	23060
Total	33048	17538	1632	14056	216	288	1156	67934

Notes: (1) Unit is doses for all values.

Table 1.2 Doses of naloxone distributed by Tier 1 distributors through syringe services/access programs (subcategory of total distribution

	2021–2024	2025	Jan–Mar 2026	Apr–Jun 2026	Jul 2026	Aug 2026	Sep 2026	Total
BPH	29798	25806	4032	6974	0	0	816	67426
PPH	35047	10244	1592	1810	628	578	502	50401
MG	10956	1546	402	200	122	106	104	13436
MAP	130490	36558	8294	7224	2548	3296	5386	193796
Total	206291	74154	14320	16208	3298	3980	6808	325059

Notes: (1) Unit is doses for all values. (2) A revision has been made to BPH March, June, September of 2021 January, April and May of 2022 as well as PPH April 2021 and February of 2023. (3) Missing data for January 2021 for PPH.

Table 1.3 Doses of naloxone distributed by Tier 1 distributors to EMS Naloxone Leave Behind Program (subcategory of total distribution)

	2022–2024	2025	Jan–Mar 2026	Apr–Jun 2026	Jul 2026	Aug 2026	Sep 2026	Total
BPH	2512	646	456	494	0	160	30	4298
PPH	1738	508	150	310	162	84	20	2972
MG	3330	1736	1104	264	96	48	410	6988
Total	7580	2890	1710	1068	258	292	460	14258

Notes: (1) Unit is doses for all values. (2) The EMS Leave Behind Program was launched in January of 2022. T1s are to provide EMS agencies across the state with kits of naloxone to provide to anyone who has refused EMS transport.

Table 2 Number of overdose reversals voluntarily reported to Tier 1 distributors (by individuals or Tier 2 distributors) and overdose reversals reported by OAG law enforcement agencies through the reporting tool called ODMAP

	2019–2024	2025	Jan–Mar 2026	Apr–Jun 2026	Jul 2026	Aug 2026	Sep 2026	Total
BPH	2933	421	172	261	97	210	42	4136
PPH	1746	187	39	43	24	25	13	2077
MG	1052	162	49	48	12	14	23	1360
MAP	3425	229	36	47	14	4	13	3768
OAG	1833	83	16	12	12	4	6	1966
OD-ME app	91	10	1	3	0	0	0	105
Total	11080	1092	313	414	159	257	97	13412

Notes: (1) Reversal totals are conservative estimates as not all reversals are reported. (2) OD-ME app is a mobile phone app developed in 2020 to support naloxone administration. (3) Overdose reversal figures may increase as backdated Tier 2 distributor and OAG incident reports are received. (4) 2019 data is July through December only. (5) Law enforcement agencies that receive naloxone from the OAG and report reversals through ODMAP are now being included. ODMAP reversal data has been added from July 2019 to present. 6) A revision has been made to reversal reports for MAP (2022), PPH (2023), OAG (2023), and MG (Q4 2025).

Works Cited

Marcella H. Sorg, Prianka Maria Sarkar, and Daniel Soucier. (2026). *Maine Monthly Overdose Report.* Orono: University of Maine, Margaret Chase Smith Policy Center.